Hyperprolactinaemia in the context of psychiatry. (January 2021)

• Record Type: Journal Article
• Authors: Romain, Karen; Fynes-Clinton, Sarah; Harmer, David; Kumar, Manoj
• Is Part Of: BJPsych advances. Volume 27:Number 1(2021)
• Page Start: 26
• Page End: 37
• Publication Date: 2021-01
• Subjects: Prolactin, -- antipsychotics, -- physical health, -- drug interactions and side-effects, -- management; Psychiatry -- Periodicals; 616.89005
• DOI: 10.1192/bja.2020.36
• Languages: English
• ISSNs: 2056-4678

Abstract

SUMMARY: Advocating for good physical healthcare for their patients is of the utmost importance to psychiatrists. This narrative review focuses on one part of this large goal, the topic of hyperprolactinaemia from the perspective of mental healthcare. For psychiatrists this often includes managing raised prolactin levels in the context of medication. However, they must consider the wider differentials of a raised prolactin level and the possible impact of treatments. For that reason, in this review we start with an overview of prolactin physiology before considering hyperprolactinaemia both in the context of antipsychotic therapy and its wider differentials, including prolactinoma. Investigation and management are considered and key practice points developed.